Related references
Note: Only part of the references are listed.Targeted Therapy for Chronic Lymphocytic Leukemia: A Glimpse Into the Future
Peter Hillmen
JOURNAL OF CLINICAL ONCOLOGY (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Focusing on plasma glycoprotein VI
Mohammad Al-Tamimi et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
Simone M. Schoenwaelder et al.
BLOOD (2011)
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2009)
Measuring soluble platelet glycoprotein VI in human plasma by ELISA
Mohammad Al-Tamimi et al.
PLATELETS (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia
Carlo Visco et al.
BLOOD (2008)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase
EE Gardiner et al.
BLOOD (2004)
Share Paper
